

## REMARKS

In the present amendment, claims 1-4 and 25 have been amended to recite selective androgen receptor modulator compound. This amendment is supported in the specification at page 22, lines 5-8. In addition, claims 1 and 25 have been amended to recite the feature of wherein said selective androgen receptor modulator compound binds to an androgen receptor ligand binding domain having the structural coordinates of Table A. This amendment is supported in the specification at page 4, lines 17-26, and page 12, lines 9-12. After entry of the present amendments, claims 1-7 and 25 will be pending. No new matter is believed to be added.

### Telephone Interview

Applicants' representative appreciates the courtesies extended during a telephone interview with Examiner Smith on January 25, 2005. During the interview, the Office Action rejections were discussed. It is believed that the present response overcomes the stated rejections and that the application is in condition for allowance.

### 35 U.S.C. § 112, first paragraph

Claims 1-7 and 25 stand rejected as purportedly not being enabled by the specification. That rejection is respectfully traversed to the extent the rejection applies to the claims as amended herein.

Applicants submit that the disclosure contains sufficient information regarding the subject matter of the claims as to enable one skilled in the pertinent art to make and use the claimed invention. Withdrawal of this rejection is respectfully requested.

### 35 U.S.C. § 103

Claims 1-7 and 25 stand rejected as purportedly being unpatentable over Thorpe et al., in view of Zhi et al. and Li et al. That rejection is respectfully traversed to the extent the rejection applies to the claims, as amended.

Claims 1 (and claims dependent thereon) and 25 are directed to methods that include the feature of administering to a patient a selective androgen receptor modulator (SARM) compound having particular features. With regard to claim 1, the SARM compound exhibits antagonist activity inhibiting growth of said hormone-dependent tumor; and exhibits no activity or agonist

activity against other, nontumor tissues containing the androgen receptor. Note that the SARM compound itself must have these features, i.e., that the SARM compound itself exhibits antagonist activity inhibiting growth of said hormone-dependent tumor; and exhibits no activity or agonist activity against other, nontumor tissues containing the androgen receptor. The combination of Thorpe et al., Zhi et al., and Li et al. does not suggest a SARM compound having the claimed features. Similar arguments apply to claim 25. Withdrawal of this rejection is respectfully requested.


### CONCLUSION

In view of the foregoing amendments and remarks, allowance of the application is respectfully requested. The Examiner is invited to contact the undersigned if there are any questions concerning the prosecution of this application.

The Commissioner is authorized to charge Deposit Account 19-3880 (Bristol-Myers Squibb Company) for any requisite fees due or to credit any overpayment.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-4091

  
Paul D. Golian  
Attorney for Applicants  
Reg. No. 42,591

Date: January 31, 2005